Loading clinical trials...
Loading clinical trials...
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination With Psychostimulants in Children and Adolescents Aged 6-17 Years With a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Conditions
Interventions
SPD503-AM
SPD503-PM
+1 more
Locations
61
United States
Harmonex Neuroscience Research
Dothan, Alabama, United States
Melmed Center
Scottsdale, Arizona, United States
Clinical Study Centers, LLC
Little Rock, Arkansas, United States
Valley Clinical Research, Inc.
El Centro, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
UCSD Department of Psychiatry
San Diego, California, United States
Start Date
September 2, 2008
Primary Completion Date
December 10, 2009
Completion Date
December 10, 2009
Last Updated
June 14, 2021
NCT07478458
NCT07465081
NCT07314333
NCT06906328
NCT07189442
NCT06711224
Lead Sponsor
Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions